TOP TEN perturbations for NM_000078 (Homo sapiens)

Organism: Homo sapiens
Gene: NM_000078
Selected probe(set): 206210_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of NM_000078 (206210_s_at) across 5339 perturbations tested by GENEVESTIGATOR:

MALT lymphoma study 1 / normal spleen tissue

Relative Expression (log2-ratio):-4.0536737
Number of Samples:8 / 6
Experimental MALT lymphoma study 1
Human t(11;18)-negative mucosa-associated lymphoid tissue (MALT) lymphoma cells.
Control normal spleen tissue
Normal human spleen tissue sample.

B-CLL study 11 (rolipram) / rolipram study 4 (normal B-cell; 20uM)

Relative Expression (log2-ratio):-3.9048605
Number of Samples:4 / 4
Experimental B-CLL study 11 (rolipram)
Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. PBMCs? samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l. ATC code:---
Control rolipram study 4 (normal B-cell; 20uM)
MACS purified resting B-cells from healthy donor peripheral blood treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. ATC code:---

colchicine study 6 (4000uM) / vehicle (medium) treated hepatocyte sample

Relative Expression (log2-ratio):3.724327
Number of Samples:2 / 2
Experimental colchicine study 6 (4000uM)
Hepatocytes treated with compound: colchicine (4000uM; CHEMBL107) for 8 hours. ATC code:
Control vehicle (medium) treated hepatocyte sample
Hepatocytes treated with vehicle (medium) for 8 hours.

B-CLL study 11 (DMSO) / vehicle (DMSO) treated normal B-cell sample

Relative Expression (log2-ratio):-3.5632277
Number of Samples:4 / 4
Experimental B-CLL study 11 (DMSO)
Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with vehicle (DMSO) for 4 hours. PBMCs? samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l.
Control vehicle (DMSO) treated normal B-cell sample
MACS purified resting B-cells from healthy donor peripheral blood treated with vehicle (DMSO) for 4 hours.

gestational age study 1 (term) / elective termination placenta (1st trim.) tissue

Relative Expression (log2-ratio):3.4384031
Number of Samples:4 / 4
Experimental gestational age study 1 (term)
Term human placenta samples obtained from scheduled uncomplicated C-sections.
Control elective termination placenta (1st trim.) tissue
First trimester placenta samples (45-59 days) obtained from uncomplicated elective termination.

HCC study 18 (early) / dysplastic liver nodule study 1

Relative Expression (log2-ratio):-3.1484652
Number of Samples:5 / 17
Experimental HCC study 18 (early)
Tumor tissue samples obtained from liver of patients with early hepatocellular carcinoma (HCC) undergoing resection or liver transplantation. Early HCC cases included well- to moderately differentiated tumors measuring 2-5 cm without vascular invasion/satellites, or 2-3 well-differentiated nodules measuring <3 cm (size range: 3-45 mm). Patients positive for HBV markers, with history of alcohol consumption, nonalcoholic steatohepatitis, hemochromatosis, other chronic liver diseases or prior locoregional treatment were excluded.
Control dysplastic liver nodule study 1
Dysplastic nodule tissue samples obtained from liver of HCV infected patients undergoing resection or liver transplantation. Patients positive for HBV markers, with history of alcohol consumption, nonalcoholic steatohepatitis, hemochromatosis, other chronic liver diseases or prior locoregional treatment were excluded.

HCC study 3 (area A) / non-tumor liver tissue

Relative Expression (log2-ratio):-3.088993
Number of Samples:13 / 37
Experimental HCC study 3 (area A)
Liver tissue biopsy sample from patients with HBV-associated HCC (hepatocellular carcinoma) after orthotopic liver transplantation (OLT) or partial hepatectomy. Tumorous sample was taken from the center of the tumor (area A). Patients were positive for hepatitis B surface antigen, antibody to hepatitis B core antigen and antibody to hepatitis B antigen and received antiviral treatment with nucleos(t)ide analogues prior to surgery.
Control non-tumor liver tissue
Histologically normal, healthy liver biopsy samples obtained from a clinically unaffected site from patients with HBV-associated HCC (hepatocellular carcinoma) after orthotopic liver transplantation (OLT) or partial hepatectomy. Non-tumorous, non-malignant sample was taken from the unaffected edge of the liver (area E). Patients were positive for hepatitis B surface antigen, antibody to hepatitis B core antigen and antibody to hepatitis B antigen and received antiviral treatment with nucleos(t)ide analogues prior to surgery.

breast cancer study 8 (primary) / normal breast tissue

Relative Expression (log2-ratio):-2.9854212
Number of Samples:13 / 4
Experimental breast cancer study 8 (primary)
Human primary infiltrating ductal carcinoma sample of a female patient with breast cancer.
Control normal breast tissue
Normal human breast samples of healthy female individuals.

HCV-related HCC study 1 / adjacent HCV-related liver tissue (LC)

Relative Expression (log2-ratio):-2.9694996
Number of Samples:5 / 4
Experimental HCV-related HCC study 1
Hepatitis C infection related human hepatocellular carcinoma sample.
Control adjacent HCV-related liver tissue (LC)
Histologically normal adjacent liver tissue of a patient with Hepatitis C infection related hepatocellular carcinoma. Patient with liver cirrhosis.

HCC study 18 (very advanced) / dysplastic liver nodule study 1

Relative Expression (log2-ratio):-2.9006786
Number of Samples:3 / 17
Experimental HCC study 18 (very advanced)
Tumor tissue samples obtained from liver of patients with very advanced hepatocellular carcinoma (HCC) undergoing resection or liver transplantation. Very advanced HCC cases included moderately to poorly differentiated tumors with macrovascular invasion or diffuse liver involvement. Patients positive for HBV markers, with history of alcohol consumption, nonalcoholic steatohepatitis, hemochromatosis, other chronic liver diseases or prior locoregional treatment were excluded.
Control dysplastic liver nodule study 1
Dysplastic nodule tissue samples obtained from liver of HCV infected patients undergoing resection or liver transplantation. Patients positive for HBV markers, with history of alcohol consumption, nonalcoholic steatohepatitis, hemochromatosis, other chronic liver diseases or prior locoregional treatment were excluded.